Anlotinib, a multitargeted tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit, has been approved for the third-line treatment of non-small cell lung cancer (NSCLC) and second-line treatment of soft tissue sarcoma in China (23, 24). This evidence concerns the gene KDR and non-small cell lung carcinoma.